Literature DB >> 23142633

Ror2-Src signaling in metastasis of mouse melanoma cells is inhibited by NRAGE.

Shan-Shan Lai1, Bin Xue, Yang Yang, Li Zhao, Chao-Shun Chu, Jia-Yin Hao, Chuan-Jun Wen.   

Abstract

The receptor tyrosine kinase (RTK) Ror2 plays important roles in developmental morphogenesis and mediates the filopodia formation in Wnt5a-induced cell migration. However, the function of Ror2 in noncanonical Wnt signaling resulting in cancer metastasis is largely unknown. Here, we show that Ror2 expression is higher in the highly metastatic murine B16-BL6 melanoma cells than in the low metastatic variant B16 cells. Overexpression of Ror2 increases the metastasis ability of B16 cells, and knockdown of Ror2 reduces the migration ability of B16-BL6 cells. Furthermore, the inhibition of Src kinase activity is critical for the Ror2-mediated cell migration upon Wnt5a treatment. The C-terminus of Ror2, which is deleted in brachydactyly type B (BDB), is essential for the mutual interaction with the SH1 domain of Src. Intriguingly, the Neurotrophin receptor-interacting MAGE homologue (NRAGE), which, as we previously reported, can remodel the cellular skeleton and inhibit cell-cell adhesion and metastasis of melanoma and pancreatic cancer, sharply blocks the interaction between Src and Ror2 and inhibits Ror2-mediated B16 cell migration by decreasing the activity of Src and focal adhesion kinase (FAK). Our data show that Ror2 is a potential factor in the tumorigenesis and metastasis in a Src-dependent manner that is negatively regulated by NRAGE.
Copyright © 2012. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23142633     DOI: 10.1016/j.cancergen.2012.09.002

Source DB:  PubMed          Journal:  Cancer Genet


  17 in total

1.  A Global Analysis of the Receptor Tyrosine Kinase-Protein Phosphatase Interactome.

Authors:  Zhong Yao; Katelyn Darowski; Nicole St-Denis; Victoria Wong; Fabian Offensperger; Annabel Villedieu; Shahreen Amin; Ramy Malty; Hiroyuki Aoki; Hongbo Guo; Yang Xu; Caterina Iorio; Max Kotlyar; Andrew Emili; Igor Jurisica; Benjamin G Neel; Mohan Babu; Anne-Claude Gingras; Igor Stagljar
Journal:  Mol Cell       Date:  2017-01-05       Impact factor: 17.970

2.  ROR2 promotes epithelial-mesenchymal transition by hyperactivating ERK in melanoma.

Authors:  María Victoria Castro; Gastón Alexis Barbero; Paula Máscolo; María Belén Villanueva; Jérémie Nsengimana; Julia Newton-Bishop; Edith Illescas; María Josefina Quezada; Pablo Lopez-Bergami
Journal:  J Cell Commun Signal       Date:  2022-06-20       Impact factor: 5.782

3.  RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy.

Authors:  Tomasz Radaszkiewicz; Michaela Nosková; Kristína Gömöryová; Olga Vondálová Blanářová; Katarzyna Anna Radaszkiewicz; Markéta Picková; Ráchel Víchová; Tomáš Gybeľ; Karol Kaiser; Lucia Demková; Lucia Kučerová; Tomáš Bárta; David Potěšil; Zbyněk Zdráhal; Karel Souček; Vítězslav Bryja
Journal:  Elife       Date:  2021-10-27       Impact factor: 8.140

Review 4.  Complex roles of NRAGE on tumor.

Authors:  Ge Zhang; Huandi Zhou; Xiaoying Xue
Journal:  Tumour Biol       Date:  2016-05-21

Review 5.  Ror2 as a therapeutic target in cancer.

Authors:  Zufan Debebe; W Kimryn Rathmell
Journal:  Pharmacol Ther       Date:  2015-01-19       Impact factor: 13.400

6.  Wnt5a promotes cancer cell invasion and proliferation by receptor-mediated endocytosis-dependent and -independent mechanisms, respectively.

Authors:  Kensaku Shojima; Akira Sato; Hideaki Hanaki; Ikuko Tsujimoto; Masahiro Nakamura; Kazunari Hattori; Yuji Sato; Keiji Dohi; Michinari Hirata; Hideki Yamamoto; Akira Kikuchi
Journal:  Sci Rep       Date:  2015-01-27       Impact factor: 4.379

7.  Expression of Ror2 mediates invasive phenotypes in renal cell carcinoma.

Authors:  Neal R Rasmussen; Zufan Debebe; Tricia M Wright; Samira A Brooks; Adam B Sendor; A Rose Brannon; A Ari Hakimi; James J Hsieh; Toni K Choueiri; Pheroze Tamboli; Jodi K Maranchie; Peter Hinds; Eric M Wallen; Catherine Simpson; Jacqueline L Norris; William P Janzen; W Kimryn Rathmell
Journal:  PLoS One       Date:  2014-12-26       Impact factor: 3.240

8.  Molecular genetics and targeted therapy of WNT-related human diseases (Review).

Authors:  Masuko Katoh; Masaru Katoh
Journal:  Int J Mol Med       Date:  2017-07-19       Impact factor: 4.101

9.  WNT5A-mediated β-catenin-independent signalling is a novel regulator of cancer cell metabolism.

Authors:  Victoria Sherwood; Shivendra Kumar Chaurasiya; Elin J Ekström; William Guilmain; Qing Liu; Tomas Koeck; Kate Brown; Karin Hansson; Margrét Agnarsdóttir; Michael Bergqvist; Karin Jirström; Fredrik Ponten; Peter James; Tommy Andersson
Journal:  Carcinogenesis       Date:  2013-11-30       Impact factor: 4.944

10.  Stage of breast cancer progression influences cellular response to activation of the WNT/planar cell polarity pathway.

Authors:  Connor D MacMillan; Hon S Leong; David W Dales; Amy E Robertson; John D Lewis; Ann F Chambers; Alan B Tuck
Journal:  Sci Rep       Date:  2014-09-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.